Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O75533
UPID:
SF3B1_HUMAN
Alternative names:
Pre-mRNA-splicing factor SF3b 155 kDa subunit; Spliceosome-associated protein 155
Alternative UPACC:
O75533; E9PCH3
Background:
Splicing factor 3B subunit 1, also known as Pre-mRNA-splicing factor SF3b 155 kDa subunit or Spliceosome-associated protein 155, plays a crucial role in pre-mRNA splicing. It is a component of the SF3B complex, essential for the 'A' complex assembly and the stable binding of U2 snRNP to the branchpoint sequence in pre-mRNA. Its involvement extends to the selective processing of microRNAs from pri-miR-17-92 and the assembly of the 'E' complex, highlighting its multifaceted role in RNA processing.
Therapeutic significance:
Understanding the role of Splicing factor 3B subunit 1 could open doors to potential therapeutic strategies.